Skip Navigation

JNCI Journal of the National Cancer Institute 2003 95(24):1818-1820; doi:10.1093/jnci/95.24.1818
© 2003 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Randal, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Randal, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2003 Oxford University Press

NEWS

Investigational Drug Access Taken To Task in Lawsuit Against FDA

Judith Randal

The first 10% of the full text of this article appears below.

Frank Burroughs was understandably heartbroken when his daughter, Abigail, a 21-year-old college senior and his only child, died of head and neck cancer in June 2001. But the grief-stricken father was also outraged by what had happened after it had become clear the previous March that standard treatments for her illness were not working.

Abigail was a patient at Johns Hopkins University Hospital, Baltimore, where one of her doctors had tempered the bad news with the suggestion that a drug that targeted the epidermal growth factor receptors (EFGRs) of her tumor just might prolong her life. Either AstraZeneca’s Iressa (gefitinib) or ImClone Systems’ Erbitux (cetuximab), the oncologist had said, would be appropriate.

However, neither drug was on the market because both were investigational. Abigail could, in principle, have been able to get one of the . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?